For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire (tezepelumab) for severe uncontrolled asthma
For more information read the patient information leaflet accessible here
For UK patients, and their caregivers, aged 12 and over who have been prescribed Tezspire▼ (tezepelumab) for severe uncontrolled asthma
It is important to know that Tezspire is not a rescue medicine so you should not use it to treat a sudden asthma attack.
If your asthma is not getting any better, or gets worse during treatment with this medicine, speak to a doctor or nurse.
This medicine has been prescribed for you only. Do not pass it on to others as it may harm them, even if their illness seems like yours.
Like all medicines, Tezspire can cause side effects, although not everybody gets them. Scroll down for more information about possible side effects or refer to the patient information leaflet linked at the top of the page. You can also find out how to report side effects at the bottom of the page.
Common side effects (these may affect up to 1 in 10 people)

Please talk to your doctor, nurse or pharmacist about what you should look out for when using Tezspire. If you experience any side effects, listed here or not, you should let them know right away.
Serious side effects and important safety information
If you notice signs of an allergic reaction, speak to a doctor or nurse immediately.
If you notice signs of an infection, speak to a doctor or nurse immediately.
If you notice signs of heart problems, speak to a doctor or nurse immediately.
Reporting side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.ukhttps://yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get as advised above.
GB-49708 | DOP: February 2024